trial · primary record
Chimeric Antigen Receptor T-Cell Therapy
Recurrent Diffuse Large B-Cell Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 36 |
| Primary completion | 2027-12-15 |
| Primary endpoint | Proportion of products successfully manufactured meeting the established release criteria with a goal of at least 1.0 x 10^6 cells/kilogram |
| Registry ID | NCT05052528 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:28.306Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05052528
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.